The challenge of managing relapsed or refractory B-cell malignancies continues to thwart the efforts of oncologists and ...

The FDA has approved a new subcutaneous (SC) formulation of pembrolizumab (Keytruda Qlex), co-formulated with ...

The study evaluated lifileucel in patients 18 years and older with unresectable or metastatic melanoma (stage IIIc or IV) who ...

Mitazalimab, in combination with standard chemotherapy, has exhibited continued promising efficacy and safety in treating ...

Helena Yu, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the treatment landscape of EGFR exon 20 insertion (ex20ins)-mutated non–small cell lung cancer (NSCLC) and how ...

During a live event, Nizar M. Tannir, MD and participants discussed how they think ahead to later lines of therapy when ...

Combination therapy with relatlimab and nivolumab enhances treatment-free survival in advanced melanoma, offering promising ...

Iberdomide is a member of a new drug class in myeloma known as CELMoD agents, which build on the established platform of ...

The US FDA has approved imlunestrant (Inluriyo) for the treatment of adult patients with estrogen receptor (ER)-positive, ...

The MEDALIST trial was a phase 3 study with patients with ESA-refractory, low-risk MDS who require transfusions. In this ...

FDA lifts REMS program for vandetanib, affirming safety in thyroid cancer treatment as healthcare providers ensure effective ...

In small cell lung cancer (SCLC), the protein DLL3 is a promising target in the development of emerging therapies. In particular, DLL3-targeted therapies have been integral in ant ...